[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369698-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369698-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","microbial-biomarker-development-for-detection-and-prognosis-of-early-stage-non-small-cell-lung-cancer","Microbial biomarker development for detection and prognosis of early-stage non-small cell lung cancer","","Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, and early detection is essential to improve outcomes. Current molecular diagnostic and prognostic biomarkers do not provide sufficient sensitivity and specificity for clinical use. Evidence links the lower airway microbiome to NSCLC, where microbial signatures correlate with development, progression, and prognosis. This review highlights recent advances and discusses opportunities from integrating microbiome data with host transcriptomics and metabolomics, while addressing limitations in sampling, sequencing, and data analysis.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/microbial-biomarker-development-for-detection-and-prognosis-of-early-stage-non-small-cell-lung-cancer/369698/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/microbial-biomarker-development-for-detection-and-prognosis-of-early-stage-non-small-cell-lung-cancer/369698.png","ImageObject",300,407,{"name":42,"@type":43},"Adam","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are early detection biomarkers important for NSCLC?","Question",{"text":63,"@type":64},"Early-stage NSCLC is more treatable, so improved diagnostic biomarkers are needed to guide care. Existing molecular biomarkers lack adequate sensitivity and specificity for clinical usefulness.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the microbiome relate to early-stage NSCLC outcomes?",{"text":68,"@type":64},"Lower airway microbiome studies suggest microbial signatures are associated with NSCLC development, progression, and prognosis. This supports the potential for microbiome-based biomarker strategies.",{"name":70,"@type":61,"acceptedAnswer":71},"What challenges hinder developing microbiome-based biomarkers?",{"text":72,"@type":64},"Key challenges include differences in sample types, sequencing methods, and approaches for data analysis. These factors complicate consistent biomarker development.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369698,1790870727,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},1374404737137,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Microbial biomarker development for detection and prognosis of early-stage non-small cell lung cancer  \nCancer Biomarkers Vol. 42(4): 1–12 © The Author(s) 2025 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/18758592251322045](DOI: 10.1177/18758592251322045)[ ](DOI: 10.1177/18758592251322045)[journals.sagepub.com/home/cbm](journals.sagepub.com/home/cbm)  \nFares Darawshy 1,2,3 , Jun-Chieh J Tsay 1,4,5, Leopoldo N Segal 1,4,6  and Harvey Pass7  \nAbstract  \nNon-small cell lung cancer (NSCLC) remains the most common cause for cancer-related mortality despite advances in treatment. Early detection is crucial for improving patient outcomes, yet current diagnostic and prognostic molecular biomarkers lack the sensitivity and speciﬁcity necessary to become clinically useful. Recent studies revealed that the lower airway microbiome play a role in NSCLC and that microbial signatures are associated with NSCLC development, progression, and prognosis, suggesting the potential for microbiome-based biomarkers for early diagnosis and risk stratiﬁcation. Here we review recent advances in the role of the local and systemic microbiome in early-stage NSCLC. Primarily, several studies have identiﬁed speciﬁc microbial taxa associated with lung cancer suggesting novel insights into disease pathogenesis and progression. Integration of microbiome data with other ‘omics’ platforms, such as host transcriptomics and metabolomics, has the potential to enhance our understanding of microbial-host interactions and may provide more comprehensive biomarker signatures. While promising, challenges remain to the development of microbiome-based biomarkers such as those related to differences in samples utilized, sequencing methods, and data analysis. Here, we discuss such challenges as well as future directions for research needed to fulﬁl the promise of microbiomebased biomarkers for changing early detection and management strategies in NSCLC.  \nKeywords  \nlung cancer, microbiome, multiomics, early diagnosis, prognosis  \nReceived: 31 May 2024; accepted: 24 January 2025  \nIntroduction  \nNon-small cell lung cancer (NSCLC) remains the leading cause of cancer-related death in the world, representing  \n25% of all newly diagnosed cancers, and is estimated to cause 44% of total cancer-related deaths.1 Early-stage NSCLC is curable with resection with 5-year survivals of 83%,65%, and 40% for TNM (Tumor, Node and  \n1 Division of Pulmonary and Critical Care Medicine, New York University Grossman School of Medicine, NYU Langone Health, New York, NY, USA 2Hadassah Medical Center, The Institute of Pulmonary Medicine, Jerusalem, Israel  \n3Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel  \n4Department of Medicine, New York University Grossman School of Medicine, NYU Langone Health, New York, NY, USA 5Division of Pulmonary and Critical Care Medicine, VA New York Harbor Healthcare System, New York, NY, USA  \n6Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, NYU Langone Health, New York, NY, USA 7Department of Cardiothoracic Surgery, NYU School of Medicine, New York, USA  \nCorresponding authors:  \nLeopoldo N Segal, Division of Pulmonary and Critical Care Medicine, New York University Grossman School of Medicine, NYU Langone Health, New York, NY, USA; Department of Medicine, New York University Grossman School of Medicine, NYU Langone Health, New York, NY, USA; Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, NYU Langone Health, New York, NY, USA.  \nEmail: [Leopoldo.Segal@nyumc.org](Leopoldo.Segal@nyumc.org)  \nHarvey Pass, Department of Cardiothoracic Surgery, NYU School of Medicine, New York, USA.  \nEmail: [Harvey.pass@nyulangone.org](Harvey.pass@nyulangone.org)  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution  \nNonCommercial","cbCaipCVotTBRc49","https://ap.wps.com/l/cbCaipCVotTBRc49","pdf",1040187,12,"English","# Abstract\n# Keywords\n# Introduction","[{\"question\":\"Why are early detection biomarkers important for NSCLC?\",\"answer\":\"Early-stage NSCLC is more treatable, so improved diagnostic biomarkers are needed to guide care. Existing molecular biomarkers lack adequate sensitivity and specificity for clinical usefulness.\"},{\"question\":\"How does the microbiome relate to early-stage NSCLC outcomes?\",\"answer\":\"Lower airway microbiome studies suggest microbial signatures are associated with NSCLC development, progression, and prognosis. This supports the potential for microbiome-based biomarker strategies.\"},{\"question\":\"What challenges hinder developing microbiome-based biomarkers?\",\"answer\":\"Key challenges include differences in sample types, sequencing methods, and approaches for data analysis. These factors complicate consistent biomarker development.\"}]","Microbial biomarker development for detection and prognosis of early-stage non-small cell lung cancer | PDF",1790184144,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/961b6bdabdf98aa38ab5d3d101ba50e6.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6adda655378ed01d2697517f7227cc30.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc75260d9b6d7b295ff8abe380d87d99.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fb31972890bc035db2957e33dbd1592e.webp",980,1306]